PRKDC and neoplasm: In total, we combined six kinase inhibitors, including two ATM inhibitors (M3541 and M4076), three ATR inhibitors (berzosertib, gartisertib, M1774), and one DNA-PK inhibitor (peposertib) with 87 anti-cancer drugs, on 62 cancer cell lines covering 12 tissues or tumor types (Fig. 1a, Supplementary Data 1 and “Data availability”).